Key clinical trials in CLL at ASH 2020
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses highlights in the field of chronic lymphocytic leukemia (CLL) from ASH 2020, including the Phase III Unity-CLL study (NCT02612311) comparing umbralisib plus ublituximab to obinutuzumab plus chlorambucil in patients with treatment naïve and relapsed/refractory CLL, and the Phase I/II BRUIN study (NCT03740529) investigating the Bruton’s tyrosine kinase inhibitor LOXO-305 in CLL/small lymphocytic leukemia. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses highlights in the field of chronic lymphocytic leukemia (CLL) from ASH 2020, including the Phase III Unity-CLL study (NCT02612311) comparing umbralisib plus ublituximab to obinutuzumab plus chlorambucil in patients with treatment naïve and relapsed/refractory CLL, and the Phase I/II BRUIN study (NCT03740529) investigating the Bruton’s tyrosine kinase inhibitor LOXO-305 in CLL/small lymphocytic leukemia. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.